Cargando…

Prognostic and Predictive Value of Carcinoembryonic Antigen and Cytokeratin-19 Fragments Levels in Advanced Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib

PURPOSE: The prognostic and predictive value of pretreatment serum levels of carcinoembryonic antigen (CEA) and cytokeratin-19 fragments (CYFRA 21-1) were assessed in advanced non-small cell lung cancer (NSCLC) patients treated with gefitinib or erlotinib. MATERIALS AND METHODS: Pretreatment CEA and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jung, Minkyu, Kim, Se Hyun, Hong, Soojung, Kang, Young Ae, Kim, Se Kyu, Chang, Joon, Rha, Sun Young, Kim, Joo Hang, Kim, Dae Joon, Cho, Byoung Chul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Yonsei University College of Medicine 2012
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423836/ https://www.ncbi.nlm.nih.gov/pubmed/22869475 http://dx.doi.org/10.3349/ymj.2012.53.5.931

Ejemplares similares

Retraction: Prognostic and Predictive Value of Carcinoembryonic Antigen and Cytokeratin-19 Fragments Levels in Advanced Non-Small Cell Lung Cancer Patients Treated with Gefitinib or Erlotinib. Yonsei Med J 2012;53:931-9.
por: Jung, Minkyu, et al.
Publicado: (2013)

Pathologic Correlation of Serum Carcinoembryonic Antigen and Cytokeratin 19 Fragment in Resected Nonsmall Cell Lung Cancer
por: Lee, Seokkee, et al.
Publicado: (2013)

Pharmacogenomic Assessment of Outcomes of Pemetrexed-Treated Patients with Adenocarcinoma of the Lung
por: Jung, Minkyu, et al.
Publicado: (2013)

EGFR Polymorphism as a Predictor of Clinical Outcome in Advanced Lung Cancer Patients Treated with EGFR-TKI
por: Jung, Minkyu, et al.
Publicado: (2012)

A Carcinoembryonic Antigen-Secreting Adenocarcinoma Arising in Tailgut Cyst : Clinical Implications of Carcinoembryonic Antigen
por: Cho, Byoung Chul, et al.
Publicado: (2005)

Elevated Serum C-Reactive Protein as a Prognostic Marker in Small Cell Lung Cancer
por: Hong, Soojung, et al.
Publicado: (2012)

Clinical efficacy of erlotinib, a salvage treatment for non-small cell lung cancer patients following gefitinib failure
por: Cho, Kyoung Min, et al.
Publicado: (2015)

Efficacy and dose of afatinib in patients with non‐small cell lung cancer after failure of prior gefitinib or erlotinib treatment
por: Choi, Hayoung, et al.
Publicado: (2021)

Elevated Squamous Cell Carcinoma Antigen, Cytokeratin 19 Fragment, and Carcinoembryonic Antigen Levels in Diabetic Nephropathy
por: Chen, Jianzhong, et al.
Publicado: (2017)

Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
por: Kim, Youjin, et al.
Publicado: (2019)

Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2005)

Clinically beneficial continued treatment with gefitinib after asymptomatic progression of lung adenocarcinoma
por: Choi, Hayoung, et al.
Publicado: (2015)

Correction: Predicting Tumor Responses to Gefitinib and Erlotinib
Publicado: (2012)

Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, and cytokeratin 19 fragments in patients with effusion from nonsmall cell lung cancer
por: Sharma, Sushil Kumar, et al.
Publicado: (2015)

Establishment of Reference Intervals of Cytokeratin 19 Fragment Antigen 21-1 in Korean Adults
por: Yoon, Sumi, et al.
Publicado: (2023)

Diagnostic Value of Galectin-3, HBME-1, Cytokeratin 19, High Molecular Weight Cytokeratin, Cyclin D1 and p27(kip1) in the Differential Diagnosis of Thyroid Nodules
por: Park, Young Joo, et al.
Publicado: (2007)

Successful erlotinib rechallenge after both gefitinib- and erlotinib-induced interstitial lung diseases
por: Arakawa, Nobuhito, et al.
Publicado: (2013)

The different central nervous system efficacy among gefitinib, erlotinib and afatinib in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer
por: Jung, Hyun Ae, et al.
Publicado: (2020)

Pemetrexed versus Gefitinib versus Erlotinib in Previously Treated Patients with Non-Small Cell Lung Cancer
por: Hong, Junshik, et al.
Publicado: (2010)

Carcinoembryonic antigen and cytokeratin-19 fragments for assessment of therapy response in non-small cell lung cancer: a systematic review and meta-analysis
por: Holdenrieder, Stefan, et al.
Publicado: (2017)

Clinical implication of tissue carcinoembryonic antigen expression in association with serum carcinoembryonic antigen in colorectal cancer
por: Aldilaijan, Abdulmohsin Fawzi, et al.
Publicado: (2023)

The Role of Brain Radiotherapy before First-Line Afatinib Therapy, Compared to Gefitinib or Erlotinib, in Patients with EGFR-Mutant Non–Small Cell Lung Cancer
por: Jung, Hyun Ae, et al.
Publicado: (2023)

Soluble epidermal growth factor receptor (sEGFR) and carcinoembryonic antigen (CEA) concentration in patients with non-small cell lung cancer: correlation with survival after erlotinib and gefitinib treatment
por: Kappers, I, et al.
Publicado: (2010)

A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)
por: Kim, Hye Ryun, et al.
Publicado: (2016)

Carcinoembryonic Antigen Level Can be Overestimated in Metabolic Syndrome
por: Kim, Kyu-Nam, et al.
Publicado: (2011)

KRAS Mutations and Primary Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib
por: Pao, William, et al.
Publicado: (2005)

Efficacy of gefitinib or erlotinib in patients with squamous cell lung cancer
por: Song, Zhengbo, et al.
Publicado: (2013)

Case of Proteinuria, Worsening Hypertension, and Glomerular Endotheliosis With Erlotinib and Gefitinib
por: Latcha, Sheron, et al.
Publicado: (2018)

Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)
por: Kim, Hye Ryun, et al.
Publicado: (2017)

Serum Carcinoembryonic Antigen for Recurrence in Colorectal Cancer Patients
por: Kim, Young Jin
Publicado: (2013)

Successful Erlotinib Treatment for a Patient with Gefitinib-Related Hepatotoxicity and Lung Adenocarcinoma Refractory to Intermittently Administered Gefitinib
por: Nagano, Tatsuya, et al.
Publicado: (2011)

Gemcitabine and Erlotinib with or without Oxaliplatin in Previously Untreated Advanced Pancreatic Cancer: A Randomized Phase II Trial
por: Lim, Sung Hee, et al.
Publicado: (2021)

Plasminogen Activator Inhibitor Type 1 (PAI-1) A15T Gene Polymorphism Is Associated with Prognosis in Patients with EGFR Mutation Positive Pulmonary Adenocarcinoma
por: Lim, Ju Eun, et al.
Publicado: (2013)

Usefulness of Bone Metabolic Markers in the Diagnosis of Bone Metastasis from Lung Cancer
por: Chung, Jae Ho, et al.
Publicado: (2005)

Association of perioperative serum carcinoembryonic antigen level and recurrence in low-risk stage IIA colon cancer
por: Kim, Han-Gil, et al.
Publicado: (2021)

Treatment with gefitinib after erlotinib-induced liver injury: a case report
por: Nakatomi, Katsumi, et al.
Publicado: (2011)

Erlotinib and gefitinib treatments of the lung cancer in an elderly patient result in gastrointestinal bleeding
por: Bai, Hongmei, et al.
Publicado: (2013)

Shikonin sensitizes wild-type EGFR NSCLC cells to erlotinib and gefitinib therapy
por: Li, Yang-Ling, et al.
Publicado: (2018)

Clinical utility of tumor marker cutoff ratio and a combination scoring system of preoperative carcinoembryonic antigen, carbohydrate antigen 19-9, carbohydrate antigen 72-4 levels in gastric cancer
por: Lee, Jong-Chan, et al.
Publicado: (2013)

CpG Island Methylator Phenotype and Methylation of Wnt Pathway Genes Together Predict Survival in Patients with Colorectal Cancer
por: Kim, Se Hyun, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_nfrjdccbm1kcj08d54ddkl5apa